Full Text View
Tabular View
No Study Results Posted
Related Studies
Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma
This study has been completed.
Study NCT00406757   Information provided by GlaxoSmithKline
First Received: November 30, 2006   Last Updated: October 8, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Additional conditions recognized in this trial
Leukemia
Leukemia, Lymphoid
Lymphoma
Lymphoma, Non-Hodgkin
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Nelarabine injection 1000mg/m2
Nelarabine injection 1500mg/m2
Nelarabine injection 650mg/m2
Nelarabine injection 400mg/m2
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services